You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advancing a Glioma Immunotherapy

    SBC: IN CYTU, INC.            Topic: 102

    DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A High Resolution Radiation Therapy Dosimetry system

    SBC: DOSEIMAGING, LLC            Topic: 399

    DESCRIPTION provided by applicant Modern radiation therapy treatment modalities such as intensity modulated radiation therapy are associated with complex dose distributions and sharp dose gradients Experimental dose validation using multidimensional high spatial resolution dosimeters is mandatory The product to be developed is a novel high resolution dosimetry system that combines reusabil ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. PEGYLATED PEPTIDES LIGANDS TARGETING RADIATION-INDUCIBLE RECEPTORS ON CANCER

    SBC: Medical Guidance Systems LLC            Topic: 102

    DESCRIPTION provided by applicant The proposed research is the study of new paradigms in both the treatment of cancer and cancer drug development This platform technology will markedly expand the number of cancer specific surface receptors and antigens that can be targeted for drug delivery using peptide ligands The general principle of this new technology is that cancer cells respond to ioni ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Carbon Fiber Off-Loading Orthosis

    SBC: Orthotic & Prosthetic Design, Inc.            Topic: 200

    DESCRIPTION provided by applicant This proposed project will further develop a CFC off loading AFO designed to offload plantar pressures and optimize patient function through maximizing plantarflexor power production During Phase I we will determine the effects of varying design characteristics of CFC off loading AFOs We will refine and create new FEA models and algorithms that predict the ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: R

    DESCRIPTION provided by applicant Noise is the most common occupational and environmental hazard thus it is not surprising that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit second only to age related hearing loss Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no medications approv ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a STAT2 knock-out hamster model for wild-type filovirus infections

    SBC: Auratus Bio LLC            Topic: 200

    DESCRIPTION provided by applicant Golden Syrian hamsters offer certain advantages over the use of other rodents in the study of a number of human diseases In the context of cancer research the histological and cytogenetic changes in the development of pancreatic cancers are similar in humans and hamsters but not in mice Hamsters are also the model species of choice for studying oncolytic ad ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans

    SBC: INTACT GENOMICS INC            Topic: R

    DESCRIPTION provided by applicant There is societal need for new therapeutic agents in our arsenal of defenses against bacterial and fungal pathogens many superbugs of which are increasingly resistant to existing antibiotics Filamentous fungi are considered promising resources for the development of novel bioactive compounds because of their great potential to produce various kinds of secon ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. IL2-based Immunotherapy for Type 2 Diabetes

    SBC: APT THERAPEUTICS, INC.            Topic: 200

    DESCRIPTION provided by applicant Principal Investigator Program Director Last First Middle Chen Ridong Abstract Type diabetes T D is a leading cause of cardiovascular disease renal failure blindness amputations and hospitalization Up to of T D patients are overweight or obese which induces chronic low grade inflammation of adipose tissue and promotes insulin resistance and T ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Reducing time, sample handling, and staff requirements for complement activation monitoring in clinical trials

    SBC: KYPHA INC.            Topic: 400

    DESCRIPTION provided by applicant Despite overwhelming evidence that the complement system is involved in kidney and cardiovascular outcomes stringent technical requirements limit its inclusion in clinical trials and diagnostics Current protocols require careful sample collectin immediate freezing and shipping to only a few specialized labs As a result while complement system proteins C ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government